Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Pharmaceutical companies Stories

2012-07-26 23:00:05

Enthusiasm among sexual dysfunction specialists for this breakthrough product in the treatment of male premature ejaculation is generating increasing demand from urologists, gynecologists and general practitioners. Huntington Beach, CA (PRWEB) July 26, 2012 Absorption Pharmaceuticals, LLC today announced the hiring of four key sales executives to meet the growing demand for Promescent® - the most effective medical solution for treating male premature ejaculation (PE). Jay Lovin, hired...

2012-07-26 10:27:38

WASHINGTON, July 26, 2012 /PRNewswire/ -- Shionogi-ViiV Healthcare LLC today announced 48-week data from the SPRING-2 Phase III study, which is evaluating the investigational integrase inhibitor dolutegravir in treatment-naive adults with HIV-1 infection. In this double-blind, double-dummy study, the proportion of study participants who were virologically suppressed (HIV-1 RNA <50 c/mL) was 88% for once-daily dolutegravir (DTG) and 85% for twice-daily raltegravir (RAL), with a 95%...

2012-07-26 02:29:02

PARIS, July 26, 2012 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q2 2012 Change on a Change at H1 2012 Change on a Change at reported constant reported constant basis exchange rates(1) basis exchange rates ----- ---------------- ----- -------------- Net sales...

2012-07-25 10:23:53

BOTHELL, WA, and VANCOUVER, July 25, 2012 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's second quarter 2012 financial results will be released on Thursday, August 2, 2012, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will discuss the company's financial results and provide an update on clinical development programs for custirsen and OGX-427. To access the webcast, log...

2012-07-25 02:30:47

LONDON, July 25, 2012 /PRNewswire/ -- Pharmaceutical group GlaxoSmithKline concedes pricing pressure in Europe had affected overall performance in the second quarter but says the Group was making "good progress" against its strategic agenda. In a video interview, CEO Sir Andrew Witty said he had seen strong performances in the Emerging Markets, Japan and the group's Consumer business. Looking forward he said he now expected full-year 2012 to be in line with 2011 as the...

2012-07-24 18:21:30

ROTKREUZ, Switzerland and PLEASANTON, Calif., July 25, 2012 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it now offers an expanded portfolio of blood screening solutions with an integrated serology testing offering*. Roche is the global leader in the blood screening business based on its long-term success in nucleic acid testing (NAT). The addition of the serology blood screening solution will further enhance its innovative offering for blood centers. The expanded...

2012-07-24 06:23:50

LIVONIA, Mich., July 24, 2012 /PRNewswire/ -- Genentech and Novartis have the best image among oncologists and hematologists, according to Market Strategies International, a market research consultancy that recently completed its 2012 Oncology Image Study. The study evaluated more than 30 attributes related to field force, corporate functions and R&D to determine which measures drive a company's image and performance in this rapidly growing, competitive marketplace. Genentech maintains...

2012-07-23 10:25:38

BRIDGEWATER, N.J., July 23, 2012 /PRNewswire/ -- Sanofi US today launched the Collaborate Activate Innovation Challenge, which will award a total of $500,000 to teams of patient advocacy groups and/or medical professional associations who deliver novel approaches to better engage patients in their own health. Based on the concept that advocates working together can make a bigger collective impact than groups working alone, the Challenge requires groups to collaborate to qualify for the...

2012-07-23 10:24:57

RIVIERA BEACH, Fla., July 23, 2012 /PRNewswire-iReach/ -- Sancilio and Company, Inc. (SCI) is pleased to announce the recent addition of Dr. Alan Dunton, Mr. Patrick Gray, Mr. Rod Jackson, Dr. Dennis Langer and Mr. Kelly Perkins to its Board of Directors. The new directors join the Company's Chairman, Dr. Frederick Sancilio, who is also Founder, President and CEO. "Our new directors are very well-known in the life sciences and financial industries. Their outstanding credentials,...

2012-07-22 22:20:39

OXFORD, England, July 23, 2012 /PRNewswire/ -- -- Award of US$125,000 will support a second clinical site in Paris, France -- Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that the US non-profit organisation, the Foundation Fighting Blindness (FFB), has granted an award of US$125,000 to the Company via its translational research arm, the Foundation Fighting Blindness Clinical...